Laks H, Marelli D, Odim J, Fazio D
Division of Cardiothoracic Surgery, University of California, Los Angeles 90095, USA.
Heart Fail Rev. 2001 Sep;6(3):221-6. doi: 10.1023/a:1011406022657.
Heart transplantation has become an acceptable treatment in pediatric patients with end-stage heart disease and complex congenital heart disease. The liberalization of recipient eligibility criteria, mainly age, along with the expansion of the donor pool has resulted in the acceptable transplantation of older recipients.
Between July 1994 and June 1998, 39 pediatric patients aged 16 days to 17.6 years (median 6.68 years) and 123 elderly patients aged 60 to 74.8 years (median 64.1 years) were transplanted at our institution. In the pediatric group, 19 had idiopathic dilated cardiomyopathy (DCM) (46 %), 14 had congenital heart disease (34 %), 4 had other etiologies of cardiomyopathy (10 %), 2 had transplant coronary artery disease (TCAD) (5 %), and 1 each had acute rejection and graft failure. In the elderly group, 71 had ischemic cardiomyopathy (58 %), 38 had DCM (31 %), 9 had other forms of cardiomyopathy (7 %), and 5 had TCAD (4 %).
Thirty-day, 1-year, and 4-year survival was 97.4 %, 87.2 %, and 70.9 % for the pediatric group and 92.7 %, 81.3 %, and 79.3 % for the elderly group. One and 4-year freedom from TCAD was 100.0 % and 85.3 % for the pediatric group and 91.9 % and 83.3 % for the elderly group.
[emsp3 ]Orthotopic heart transplantation is effective for the treatment of irreparable congenital and end-stage heart disease. It provides excellent long-term results in both the very young and elderly.
心脏移植已成为患有终末期心脏病和复杂先天性心脏病的儿科患者可接受的治疗方法。受者资格标准的放宽,主要是年龄标准,以及供体库的扩大,使得年龄较大的受者也能接受移植。
1994年7月至1998年6月期间,我院对39例年龄在16天至17.6岁(中位年龄6.68岁)的儿科患者和123例年龄在60至74.8岁(中位年龄64.1岁)的老年患者进行了心脏移植。儿科组中,19例患有特发性扩张型心肌病(DCM)(46%),14例患有先天性心脏病(34%),4例患有其他心肌病病因(10%),2例患有移植冠状动脉疾病(TCAD)(5%),1例分别发生急性排斥反应和移植物衰竭。老年组中,71例患有缺血性心肌病(58%),38例患有DCM(31%),9例患有其他形式的心肌病(7%),5例患有TCAD(4%)。
儿科组的30天、1年和4年生存率分别为97.4%、87.2%和70.9%,老年组分别为92.7%、81.3%和79.3%。儿科组1年和4年无TCAD生存率分别为100.0%和85.3%,老年组分别为91.9%和83.3%。
原位心脏移植对治疗无法修复的先天性和终末期心脏病有效。它在非常年轻和老年患者中都能提供出色的长期效果。